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To estimate the impact of the Huntington gene on mortality,
we studied ten families with Huntington disease, whose records
started before 1800. We investigated mortality from 1800 to
1997 in 257 carriers of the Huntington gene and 474 potential
carriers. Follow-up extended from age 20 years to the date of
death or end-of-study date. The observed deaths were com-
pared with those expected on the basis of the general popula-
tion, adjusted for sex, age, and calendar time. To study the
influence of the famüy and parental transmission, we calcu-
lated hazard ratios adjusted for sex, probability of carrying the
gene, and year of birth. In 25,013 person-years, 420 deaths
occurred, whereas 278 deaths were expected [standardized mor-
tality ratio = 1.5; 95% confidence interval (Cl) = 1.4-1.7].
Excess mortality was confined to ages 40-70 years (Standard-
ized mortality ratio = 2.2; 95% Cl = 1.9-2.4). To study the
evolution of mortality over time in this age group, we calcu-
lated absolute mortality rates per calendar period. From 1800
onward, mortality rates in the general population continuously
declined, but among the families with Huntington disease this
decline was absent. There were only small differences in risk
between families, and the relative risk for patemal over ma-
temal transmission was 1.2 (95% Cl = 0.9-1.5). Our main
finding is that persons who carry the Huntington gene and
reach middle age have not benefited from advances in medical
care and overall increase in life expectancy. (Epidemiology
1999-.10-.706-710)
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Huntington disease (HD) is a slowly progressive autoso-
mal dominant neurodegenerative disease with complete
penetrance.1 Clinical manifestation consists of gradually
evolving involuntary movements (chorea), progressive
dementia, and psychiatric disturbances, especially mood
disorders and personality changes. HD affects between 3
and 7 per 100,000 individuals in white populations, but
it has been described in populations of many different
ancestries.1 Onset occurs at about 40 years of age, al-
though extremes of 2 and 80 years have been reported.1'4
TKe mean duration of the disease is 16 years and is
independent of the age at onset.1'3·5'6 There is no treat-
ment to prevent the onset or to delay the fatal course of
the disease. Approximately 80% of juvenüe patients
inherit the HD gene from their father,2·4·5·7"10 whereas a
preponderance of maternal transmission has been noted
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in late-onset disease.11"13 In Dutch late-onset patients,
die sex of the affected parent was nearly equally distrib-
uted,4·8 In addition it has been reported that, akhough
the mean age at onset between affected mothers and
their offspring did not differ greatly, affected cnildren of
affected fathers had a Iower mean age at onset than their
fathers.14 This anticipation phenomenon was already
reported in the 1970s äs a difference in age at death
between offspring of men and their fathets.15·16
In 1993, the HD gene was identified äs an expansion
and instability of a specific GAG trinucleotide repeat on
chromosome 4pl6.3.17 In HD patients, this highly poly-
morphic GAG repeat is expanded to a ränge of 36 to 121
copies. Age at onset of the disorder is inversely corre-
lated with the number of GAG repeats,18"20 but there
was a wide ränge of age at onset for any specific repeat
number.21 The repeat length accounts for approximately
50% of the Variation in the age at onset.20 During
meioses, the HD repeat is unstable, showing both in-
creases and decreases in size with the largest expansions
in alleles of paternal origin. This finding could be an
explanation for the anticipation phenomenon.18'20
Because anticipation may be observed äs a conse-
quence of ascertainment bias, th.e unbiased impact of the
HD gene and its Variation between families and line of
inheritance can best be studied during long-term follow-
up. We developed a method to study the survival of
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family members retrospectively by extending the fol-
low-up to the past.22 The aim of the present study was to
compare mortality from 1800 through 1997 in members
of HD famihes with that in the general Dutch popula-
tion using the Family Tree Mortality Ratio method. The
amount of excess mortahty in the HD families provides
an estimate of the impact of gene carriership on life
expectancy. In addition, in these ten families we deter-
mined the influence of transmission of the HD gene




Since the mid-1930s, clinical and genealogical data of
the great majority of HD patients and their families in
the Netherlands have been compiled in the Leiden
Röster.4·6·8·23 The pedigree Information is obtained via
the families and is verified and extended using municipal
registers and national archives, in which all births and
deaths have been reported since 1811, and using parish
records for the period before 1811. The Leiden Roster is
in compliance with Dutch legislation regarding privacy
and protection of medical data. From these files, ten
large HD pedigrees, between seven and nine successive
generations, have been selected with patients in at least
two branches and with a clear inheritance pattern. All
proven, obligate, and potential carriers of the HD gene
were included in this study. In the present generations
the diagnosis of HD was confirmed by DNA analysis. In
the previous generations, we used pathologic records and
Mendelian reasoning to identify persons with a 50% or
100% probability of carrying the HD gene. Obligate
carriers were family members who had passed on the HD
gene from common ancestors to their affected offspring.
Potential carriers were defined äs all first-degree relatives
of carriers (that is, children and siblings). Thus, Men-
delian probabilities can be assigned to all individuals in
the pedigree. Using parish records, municipal registers,
and national archives, we verified and completed the
dates of birth and death for all proven, obligate, and
potential HD carriers. Follow-up for all individuals ex-
tended from 20 years after the date of birth to the date
of death or to June 30,1997. The reason for ignoring the
first 20 years of life was that the obligate carriers, who
have passed on the HD gene to their affected offspring,
had to be alive at the Start of the reproductive period.
Moreover, we did not expect an impact of the HD gene
before the procreation period. This approach of con-
structing pedigrees to extend the number of carriers into
the previous generations has been described in former
reports on mortality in hereditary diseases and is called
the Family Tree Mortality Ratio method.22·24"26
STATISTICAL ANALYSIS
The overall mortality of the study population (observed)
was compared with that of the Dutch general population
(expected) adjusted for age, sex, and calendar period.
The ratio of observed to expected number of deaths is
the standardized mortahty ratio (SMR), a rate ratio
measure. The expected mortality was calculated by mul-
tiplying the total number of years lived by the study
population with the sex-, age-, and calendar period-
specific population mortality rates from the annual re-
ports of the Netherlands Central Bureau of Statistics,
using the Computer program Person-Years.27 Confidence
limits for the SMR are based on a Poisson distribution
for the observed number of deaths.28 The calendar peri-
ods were divided into a 50-year interval from 1800 to
1849, 20-year intervals from 1850 to 1889, a 15-year
interval from 1890 to 1904, and 10-year intervals from
1905 to 1997. To each of these periods we applied the
population mortality rates of the midinterval year, sub-
divided by sex and into 5-year age groups.
Because of distinctions in structure of person-years
over the calendar and age groups, one SMR cannot be
compared with another SMR. Therefore, to study the
influence of the family or of line of inheritance, we
performed Cox regression analysis. In the two oldest
generations it was, by definition, not known which par-
ent transmitted the HD gene. The multivariate analysis
calculated hazard ratios for the ten families and for
parental transmission adjusted for sex, probability of
carrying the HD gene, and year of birth.
Results
After removal of spouses and family members with less
than 50% probability of carrying the HD gene, 849
persons from ten HD families had at least a 50% prob-
ability of carrying the HD gene. Of these, 731 individ-
uals were 20 years of age and older and contributed
person-years to the analysis. From these ten families, 143
affected men and 114 affected women were identified
with certainty, with respectively 123 and 88 persons
dying during the study period; 241 men and 233 women
were potential HD gene carriers, with respectively 119
and 90 dying in the study period. The mean life expect-
ancy in men was 63 years [95% confidence interval
(CI) = 61-65 years], and that in women was 68 years
(95% CI = 65-70 years). The mean life expectancy in
proven and obligate HD carriers was 59 years (95% CI =
57-61 years), and that in potential HD carriers was 73
years (95% CI = 71-75 years).
Of a total of 25,013 person-years, 420 deaths were
counted (242 in men and 178 in women) (Table 1). The
expected number of deaths was 278 (154 in men and 124
in women), leading to an overall SMR of 1.5 (95% CI =
1.4-1.7) in both men and women. Table l shows the
characteristics and relative mortality for the ten HD
families separately. In all families there was excess mor-
tality, although there were differences in the magnitude
of the SMR.
The excess mortality was limited to the age group
40-70 years (SMR 249/115 = 2.2; 95% CI = 1.9-2.4)
and was strengest in the age group 45-60 years (SMR
137/51 = 2.7; 95% CI = 2.3-3.2). To determine the
evolution of mortality in this particular age group, in
which the HD gene expresses its major impact, we
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TABLE 1. Characteristics and Relative Mortality in the Ten Huntington Disease Families, from 20 Years of Age Onward
















































































































HD = Huntington disease; SMR = standardized mortality ratio.
calculated the absolute mortality rates per l ,000 person-
years in the HD families and in the general Dutch
population per calendar period, adjusted for the age
structure of the HD families over the whole time period
(Figure 1). During the past 2 centuries, the absolute
mortality rates of the general Dutch population contin-
uously declined, but among the HD family members this
decline was absent. Because of this phenomenon, the
relative risk increased from 1.3 in the 19th Century to 3.7
in the period 1975—1997 for the age group 40-70 years,
Using Cox regression analysis, we studied the influ-
ence of the family and the line of inheritance. The
differences in risk among the HD families were small
-(Table 2), given that the smallest family (family 4) had
the highest hazard ratio. Furthermore, the year of birth
did not influence the mortality rate (äs was already
shown in Figure l by the fact that the absolute mortality
rate remained stable over 2 centuries in the HD family
members). The risk of dying was 1.4 times greater for
men than for women, and proven and obligate carriers
IHD families ODutch population
1800-1890 1890-1915 1915-1935 1935-1955 1955-1975 1975-1997
RR 1.3 1.4 2.3 3.1 2.6 3.7
Calendar periods
FIGURE 1. Absolute mortality rate per 1,000 person-
years (py) in the HD families and in the general Dutch
population according to calendar periods in the age group
40-70 years, adjusted for the age structure of the HD fam-
ilies over the whole time period. RR = rate ratio, the ad-
justed mortality rate of the HD families to the adjusted
mortality rate of the general Dutch population per calendar
period.
had a higher mortality rate than potential carriers (Ta-
ble 2). The SMR for both paternal and maternal inher-
itance was 1.7 (95% CI = 1.5-1.9), but the SMR for
unknown transmission (meaning the first and second
generations) was equal to unity. In a Cox regression
model adjusted for family, sex, probability of carrying the
HD gene, and year of birth, individuals who inherited
the HD gene from their father had an 18% higher risk of
dying than family members who inherited the HD gene
from their mother (Table 2). This effect was apparent in
four families, but in three families the risk of dying might
be lower for paternal than for maternal transmission
(Table 3). In most families both paternal and maternal
inheritance were present, although in families 4 and 5
most individuals inherited the HD gene from their
mother, and in families 2, 6, and 10 there were more
individuals who inherited the HD gene from their father
(Table 3).
TABLE 2. Adjusted Hazard Ratio (HR) and 95% CI for
















































































Epidemiology November 1999, Vol. 10 No. t>
TABLE 3. Hazard Ratio (HR) and 95% Cl of Paternal vs
Maternal Inheritance for Mortality from 20 Years of Age
Onward, Using Cox Regression Analysis Adjusted for Sex,
















































We found a secular increase of relative mortality in the
HD families, mainly because of decreasing mortality
rates in the general Dutch population over the past 2
centuries. This means that the impact of the HD gene is
rising: in comparison with the general Dutch population
it becomes more disadvantageous to carry this gene. The
fact that the mortality rates in the HD family members
remained stable over calendar time implies that the
duration of the disease has not changed (around 16
years), and it reflects the absence of medical therapy to
delay the disease progression.1
According to the literature, in some families, HD
follows a milder course, with longer survival.1 In our
study, all HD families showed excess mortality, and the
SMR varied between 1.3 and 5.7. The most important
factor associated with differences in mortality rate was
the number of individuals contributed to the analysis by
a specific family: the smallest family (family 4) had the
highest risk. Taking the family size into account, these
HD families might have a homogeneous genetic back-
ground (Table 2).
In the literature, the mean age at death is around 60
years, but it differs between the studies on the basis of
the interval of observation.1'15'16·29·30 In our study, the
mean life expectancy (corrected for surviving individu-
als) for affected family members and their first-degree
relatives was 65 years of age. Comparing the mean life
expectancy of men and women (difference of 5 years)
with the adjusted hazard ratio for men vs women (43%
increase) and the mean life expectancy of certain (prov-
en and obligate) carriers and potential carriers (differ-
ence of 14 years) with the mortality risk for certain vs
potential carriers (155% increase; Table 2), it becomes
clear that an increase of approximately 10% in risk
might be equated with a decrease of l year in mean life
expectancy. Thus, an adjusted hazard ratio of 1.2 for
paternal over maternal transmission might imply that all
offspring of affected fathers will, on average, live 2 years
shorter than offspring of affected mothers. Bird et al15
and Vegter-van der Vlis et al16 have presented this
finding although the purpose of these studies was to
determine anticipation between generations. In the lit-
MORTALITY WITH HUNTINGTON DISEASE 709
erature, there has been discussion of why and how pa-
ternal transmission can lead to earlier disease onset in
their offspring.5·7·9'10·13·14'31·32 After the identification of
the HD gene,17 the mechanism of expansion and insta-
btlity of the GAG trinucleotide repeat length has partly
clarified the discussion.18"21·33·34
The mortality rate for an individual was slightly
higher if the HD gene was transmitted through the
father, but this was not true for all families. In at least
three of the studied HD families (families 2, 8, and 9),
the line of inheritance had no influence on the mortality
rate, and might even have had a reverse effect. In
addition, if paternal transmission leads to earlier age at
onset and therefore to higher mortality, one would ex-
pect a higher mortality rate in families with mainly
paternal transmission äs compared with families with
mainly matemal transmission. Nevertheless, in the fam-
ilies under investigation this was not the case: the two
families with preponderantly maternal inheritance had
slightly higher mortality rates than the referent family,
whereas the families with primarily paternal inheritance
all had slightly lower mortality rates than the referent
family. Because this phenomenon was most prominent
in smaller families, this may be a chance finding. Our
main finding is that persons who carry the HD gene and
reach middle age have benefited less from any advance
in medical care and overall expansion in life expectancy
than have individuals of the general Dutch population.
HD carriership has become progressively more disadvan-
tageous.
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